|
US6036957A
(en)
*
|
1990-03-30 |
2000-03-14 |
Autoimmune, Inc. |
Suppression of T-cell proliferation using peptide fragments of myelin basic protein
|
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
|
IL113812A
(en)
*
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
JP2002503658A
(ja)
*
|
1998-02-13 |
2002-02-05 |
オートイミューン インク |
ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
|
|
EP1098902A4
(en)
|
1998-07-23 |
2002-07-24 |
Yeda Res & Dev |
TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
ES2408706T3
(es)
|
1998-09-25 |
2013-06-21 |
Yeda Research And Development Co., Ltd. |
Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico
|
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
|
HK1054507B
(zh)
*
|
2000-01-20 |
2008-10-31 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
|
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
MXPA02008023A
(es)
*
|
2000-02-18 |
2005-06-30 |
Yeda Res & Dev |
Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
|
|
CA2411536A1
(en)
*
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DE60116467T2
(de)
*
|
2000-06-07 |
2006-11-02 |
Yeda Research And Development Co., Ltd. |
Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
|
|
IL148202A0
(en)
*
|
2000-06-20 |
2002-09-12 |
Caprion Pharmaceuticals Inc |
Copolymers and methods of treating prion-related diseases
|
|
WO2002076503A1
(en)
*
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
|
EP1459065B1
(en)
|
2001-12-04 |
2010-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
US7351686B2
(en)
*
|
2001-12-06 |
2008-04-01 |
Yeda Research And Development Co. Ltd. |
Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
|
|
WO2003059387A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
WO2004060265A2
(en)
|
2003-01-07 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
NZ569331A
(en)
*
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
CA2518079A1
(en)
*
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
AU2004227852B2
(en)
|
2003-03-31 |
2010-01-14 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
|
JP2007509981A
(ja)
*
|
2003-10-31 |
2007-04-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
薬物デリバリー用ナノ粒子
|
|
CA2546077C
(en)
|
2003-11-12 |
2016-07-05 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
DK1701730T3
(da)
|
2003-12-09 |
2013-11-25 |
Yeda Res & Dev |
Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
|
|
AU2005211424A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
|
RU2006134701A
(ru)
*
|
2004-03-01 |
2008-04-10 |
Пептиммьюн |
Способы и композиции для лечения аутоиммунных заболеваний
|
|
EP1778286A4
(en)
*
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
CA2565819A1
(en)
|
2004-05-07 |
2005-12-01 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
NZ578727A
(en)
|
2004-06-25 |
2011-03-31 |
Brigham & Womens Hospital |
Proteosome compositions and methods for treating neurological disorders
|
|
DK1799703T3
(da)
*
|
2004-09-09 |
2010-04-19 |
Teva Pharma |
Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
|
|
HRP20160455T1
(hr)
*
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
DE602005016292D1
(de)
*
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
|
ES2541780T3
(es)
*
|
2004-11-29 |
2015-07-24 |
Yeda Research And Development Co., Ltd. |
Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
|
|
US20060172942A1
(en)
*
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
RS52867B
(sr)
*
|
2005-02-17 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
|
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20060240463A1
(en)
*
|
2005-04-25 |
2006-10-26 |
Rappaport Family Institute For Research In The Medical Sciences |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
WO2007092451A2
(en)
|
2006-02-06 |
2007-08-16 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
|
JP2009536157A
(ja)
|
2006-04-13 |
2009-10-08 |
ペプチミューン，インコーポレイテッド |
エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
|
|
WO2007127977A2
(en)
*
|
2006-04-28 |
2007-11-08 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating peptide mixtures
|
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
|
JP5412280B2
(ja)
|
2006-06-28 |
2014-02-12 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
加齢性黄斑変性症の治療法
|
|
SI2046817T1
(sl)
*
|
2006-07-05 |
2010-04-30 |
Momenta Pharmaceuticals Inc |
Izboljšani postopek za pripravo kopolimera-1
|
|
ES2477232T5
(es)
|
2007-06-21 |
2017-11-23 |
Momenta Pharmaceuticals, Inc. |
Análisis de copolímeros
|
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
|
EP2173766A1
(en)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
AP3467A
(en)
|
2007-10-16 |
2015-11-30 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
|
US20090124573A1
(en)
|
2007-11-09 |
2009-05-14 |
Sarkis Mazmanian |
Immunomodulating compounds and related compositions and methods
|
|
WO2009070298A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Teva Pharmaceutical Industries, Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
ES2449865T5
(es)
*
|
2008-04-16 |
2022-11-18 |
Momenta Pharmaceuticals Inc |
Análisis de composiciones de copolímeros de aminoácidos
|
|
KR20110059606A
(ko)
*
|
2008-08-07 |
2011-06-02 |
시노팜 타이완 리미티드 |
글라티라머 아세테이트의 합성
|
|
PL2307448T3
(pl)
*
|
2008-08-07 |
2015-10-30 |
Sigma Aldrich Co Llc |
Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
|
|
AR074881A1
(es)
*
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
|
RU2011144566A
(ru)
|
2009-04-03 |
2013-05-10 |
Момента Фармасьютикалз, Инк. |
Контроль сополимерных композиций
|
|
EP2438080B1
(en)
|
2009-06-04 |
2013-12-04 |
Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) |
Process for the preparation of copolymer-1 (cop-1), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine for the treatment of multiple sclerosis
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
|
RS55607B1
(sr)
|
2009-08-20 |
2017-06-30 |
Yeda Research & Development Company Ltd |
Niskofrekventna terapija glatiramer acetatom
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
WO2011080733A1
(en)
|
2010-01-04 |
2011-07-07 |
Mapi Pharma Limited |
Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
WO2011086470A1
(en)
|
2010-01-13 |
2011-07-21 |
Ramot At Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
HUE040658T2
(hu)
|
2010-04-07 |
2019-03-28 |
California Inst Of Techn |
Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
|
|
MX2012012489A
(es)
*
|
2010-04-27 |
2012-12-17 |
Reddys Lab Ltd Dr |
Preparacion de polipeptidos y sales de los mismos.
|
|
WO2011146910A1
(en)
|
2010-05-20 |
2011-11-24 |
Round June L |
Antigen specific tregs and related compositions, methods and systems
|
|
JP2013535474A
(ja)
|
2010-07-29 |
2013-09-12 |
ドクター レディズ ラボラトリーズ リミテッド |
グラチラマー酢酸塩の分子量マーカー
|
|
EA025780B1
(ru)
|
2010-10-11 |
2017-01-30 |
Тева Фармасьютикал Индастриз Лтд. |
Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
|
|
ES2654291T3
(es)
|
2011-02-14 |
2018-02-13 |
Usv Private Limited |
Copolímero-1, proceso para la preparación y sus métodos de análisis
|
|
ES2601892T3
(es)
*
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
|
US9539281B2
(en)
|
2011-07-12 |
2017-01-10 |
The Brigham And Women's Hospital, Inc. |
Lipid-containing PSA compositions, methods of isolation and methods of use thereof
|
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
MX2014004309A
(es)
|
2011-10-10 |
2015-07-06 |
Teva Pharma |
Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
|
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
|
WO2014058976A2
(en)
|
2012-10-10 |
2014-04-17 |
Teva Pharmaceutical Industries Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
EP2774639B1
(en)
|
2013-03-08 |
2014-12-10 |
Teva Pharmaceutical Industries, Ltd. |
Re-useable injector device for syringe
|
|
EP2774640B1
(en)
|
2013-03-08 |
2014-12-31 |
Teva Pharmaceutical Industries, Ltd. |
Re-useable injector device for syringe
|
|
CA2903805A1
(en)
|
2013-03-14 |
2014-10-02 |
Mylan Inc. |
Glatiramer acetate response biomarker mrna potency assay
|
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
WO2014182966A1
(en)
|
2013-05-10 |
2014-11-13 |
California Institute Of Technology |
Probiotic prevention and treatment of colon cancer
|
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
EP3060684A4
(en)
|
2013-10-24 |
2017-06-07 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
|
EP3090064B1
(en)
|
2013-12-31 |
2019-11-13 |
Yeda Research and Development Co. Ltd. |
Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
|
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US11047855B2
(en)
|
2015-03-01 |
2021-06-29 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
|
WO2016201342A1
(en)
|
2015-06-10 |
2016-12-15 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
|
CN108135167B
(zh)
|
2015-08-19 |
2021-07-09 |
哈佛学院院长及董事 |
脂化psa组合物和方法
|
|
EP3147667B1
(en)
|
2015-09-24 |
2019-06-12 |
CHEMI S.p.A. |
Analysis of the molecular weight distribution of complex polypeptide mixtures
|
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
|
EP3478300B1
(en)
|
2016-06-30 |
2022-08-24 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
WO2018014012A1
(en)
|
2016-07-15 |
2018-01-18 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
WO2018042423A1
(en)
|
2016-08-28 |
2018-03-08 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
AU2017319728B2
(en)
|
2016-08-31 |
2024-09-05 |
Mapi Pharma Ltd |
Depot systems comprising glatiramer acetate
|
|
IL316573A
(en)
|
2017-03-26 |
2024-12-01 |
Mapi Pharma Ltd |
Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
|
|
EP3624815A4
(en)
|
2017-05-15 |
2021-01-20 |
Stem Cell Medicine Ltd. |
TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
|
|
IL269893B2
(en)
|
2017-05-15 |
2023-10-01 |
Stem Cell Medicine Ltd |
Treatment of multiple sclerosis with adipose-derived stem cells
|
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|